PT  - JOURNAL ARTICLE
AU  - Per Jensen
AU  - Ling Feng
AU  - Ian Law
AU  - Claus Svarer
AU  - Gitte M. Knudsen
AU  - Jens D. Mikkelsen
AU  - Robin de Nijs
AU  - Vibeke A. Larsen
AU  - Agnete Dyssegaard
AU  - Gerda Thomsen
AU  - Walter Fischer
AU  - Denis Guilloteau
AU  - Lars H. Pinborg
TI  - TSPO Imaging in Glioblastoma Multiforme: A Direct Comparison Between <sup>123</sup>I-CLINDE SPECT, <sup>18</sup>F-FET PET, and Gadolinium-Enhanced MR Imaging
AID  - 10.2967/jnumed.115.158998
DP  - 2015 Sep 01
TA  - Journal of Nuclear Medicine
PG  - 1386--1390
VI  - 56
IP  - 9
4099  - http://jnm.snmjournals.org/content/56/9/1386.short
4100  - http://jnm.snmjournals.org/content/56/9/1386.full
SO  - J Nucl Med2015 Sep 01; 56
AB  - Here we compare translocator protein (TSPO) imaging using 6-chloro-2-(4′-123I-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide SPECT (123I-CLINDE) and amino acid transport imaging using O-(2-18F-fluoroethyl)-l-tyrosine PET (18F-FET) and investigate whether 123I-CLINDE is superior to 18F-FET in predicting progression of glioblastoma multiforme (GBM) at follow-up. Methods: Three patients with World Health Organization grade IV GBM were scanned with 123I-CLINDE SPECT, 18F-FET PET, and gadolinium-enhanced MR imaging. Molecular imaging data were compared with follow-up gadolinium-enhanced MR images or contrast-enhanced CT scans. Results: The percentage overlap between volumes of interest (VOIs) of increased 18F-FET uptake and 123I-CLINDE binding was variable (12%–42%). The percentage overlap of MR imaging baseline VOIs was greater for 18F-FET (79%–93%) than 123I-CLINDE (15%–30%). In contrast, VOIs of increased contrast enhancement at follow-up compared with baseline overlapped to a greater extent with baseline 123I-CLINDE VOIs than 18F-FET VOIs (21% vs. 8% and 72% vs. 55%). Conclusion: Our preliminary results suggest that TSPO brain imaging in GBM may be a useful tool for predicting tumor progression at follow-up and may be less susceptible to changes in blood–brain barrier permeability than 18F-FET. Larger studies are warranted to test the clinical potential of TSPO imaging in GBM, including presurgical planning and radiotherapy.